Información del artículo
La esclerosis sistémica (ES) se caracteriza por ser una enfermedad cuyo manejo resulta, en muchas ocasiones, frustrante tanto para el paciente como para el médico, dada la falta de terapias eficaces. Resulta cuando menos esperanzador que en la última década se hayan producido novedades que nos ayudan a realizar un mejor seguimiento de los pacientes y que se hayan abierto las puertas hacia nuevas y futuras terapias.
Palabras clave:
Esclerodermia
Esclerosis sistémica
Nuevas terapias
Aspectos novedosos
EUSAR
Patrones capilaroscópicos
Systemic sclerosis (SS) is a disease whose handling is, in many occasions, frustrating for the patient as for the doctor, given the lack of effective therapies. It is hopeful at least, the fact that in the last decade new features have taken place that help us to make a better pursuit of the patients and who have opened the doors towards new and future therapies.
Key words:
Scleroderma
Systemic sclerosis
New therapies
New features
EUSTAR
Capilaroscopic paterns
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Cutolo, C. Pizzorni, M. Tuccio, A. Burroni, C. Craviotto, M. Basso, et al.
Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
Rheumatology (Oxford), 43 (2004), pp. 719-726
[2.]
M.T. Duruöz, S. Poiraudeau, J. Fermanian, C.J. Menkes, B. Amor, M. Dougados, et al.
Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap.
J Rheumatol, 23 (1996), pp. 1167-1172
[3.]
L.M. Brower, J.L. Poole.
Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma).
Arthritis Rheum, 51 (2004), pp. 805-809
[4.]
L. Mouthon, F. Rannou, A. Bérezné, C. Pagnoux, J.P. Arène, E. Foïs, et al.
Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap In System Sclerosis scale (MHISS).
Ann Rheum Dis, 66 (2007), pp. 1651-1655
[5.]
D.L. Kamen, F.M. Wigley, A.N. Brown.
Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma – a different kind of renal crisis.
J Rheumatol, 33 (2006), pp. 1886-1888
[6.]
M. Tomioka, F. Hinoshita, N. Miyauchi, Y. Akiyama, S. Saima, M. Hiroe.
ANCA-related crescentic glomerulonephritis in a patient with scleroderma without marked dermatological change and malignant hypertension.
J Intern Med, 43 (2004), pp. 496-502
[7.]
L. Arnaud, A. Huart, E. Plaisier, H. Francois, B. Mougenot, K. Tiev, et al.
ANCA-related crescentic glomerulonephritis in systemic sclerosis: revisiting the “normotensive scleroderma renal crisis”.
Clin Nephrol, 68 (2007), pp. 165-170
[8.]
P.P. Sfikakis, C. Papamichael, K.S. Stamatelopoulos, D. Tousoulis, K.G. Fragiadaki, P. Katsichti, et al.
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Arthritis Rheum, 56 (2007), pp. 1985-1993
[9.]
J.H. Korn, M. Mayes, M. Matucci-Cerinic, M. Rainisio, J. Pope, E. Hachulla.
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Arthritis Rheum, 50 (2004), pp. 3985-3993
[11.]
B.K. Sastry, C. Narasimhan, N.K. Reddy, B.S. Raju.
Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.
J Am Coll Cardiol, 43 (2004), pp. 1149-1153
[12.]
R. Fries, K. Shariat, H. Von Wilmowsky, M. Böhm.
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Circulation, 112 (2005), pp. 2980-2985
[13.]
R.K. Hoyles, R.W. Ellis, J. Wellsbury, B. Lees, P. Newlands, N.S. Goh, et al.
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Arthritis Rheum, 54 (2006), pp. 3962-3970
[14.]
D.P. Tashkin, R. Elashoff, P.J. Clements, M.D. Roth, D.E. Furst, R.M. Silver, et al.
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Am J Respir Crit Care Med, 176 (2007), pp. 1026-1034
[15.]
S.N. Liossis, A. Bounas, A.P. Andonopoulos.
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.
Rheumatology (Oxford), 45 (2006), pp. 1005-1008
[16.]
J.J. Swigris, A.L. Olson, A. Fischer, D.A. Lynch, G.P. Cosgrove, S.K. Frankel.
Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.
Chest, 130 (2006), pp. 30-36
[17.]
C. Paone, I. Chiarolanza, G. Cuomo, L. Ruocco, S. Vettori, M. Menegozzo.
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy.
Clin Exp Rheumatol, 25 (2007), pp. 613-616
[18.]
J.H. Distler, A. Jüngel, L.C. Huber, U. Schulze-Horsel, J. Zwerina, R.E. Gay, et al.
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Arthritis Rheum, 56 (2007), pp. 311-322
[19.]
R. Souza, O. Sitbon, F. Parent, G. Simonneau, M. Humbert.
Long term imatinib treatment in pulmonary arterial hypertension.
Thorax, 61 (2006), pp. 736
[20.]
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56:323-33.
[21.]
B. Santiago, I. Gutierrez-Cañas, J. Dotor, G. Palao, J.J. Lasarte, J. Ruiz, et al.
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis.
J Invest Dermatol, 125 (2005), pp. 450-455
Copyright © 2008. Elsevier España S.L. Barcelona
